← All trials
NCT05587309
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2022
- Primary completion
- Jun 30, 2024
- Completion date
- Dec 29, 2024
- First posted
- Oct 20, 2022
- Last posted
- Oct 20, 2022
- Enrollment
- 1250
- Arms / groups
- 5 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Braintree LaboratoriesLead sponsor
- Sebela PharmaceuticalsStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.